Menu

Recent Interviews

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


23. January 2020 | 05:50 CET

Berenberg says "buy": Next recommendation for MPH investment M1 Kliniken AG

  • Clinic

The analysts at Berenberg have begun coverage of M1 Klinken AG and have recommended the share as a buy. With more than 70 doctors and over 200,000 treatments annually, M1 is the market leader for beauty medicine in Germany. Thanks to its strategy "highest quality at the best price", the company has been able to achieve annual growth rates of around 30% since 2014. The investment of MPH Health Care, which is also listed on the stock exchange, should also grow significantly in the future. The driving forces are the increasing market penetration in Germany and the international rollout. The analysts expect EBIT to grow by 30% annually until 2022 and recommend buying the M1 share with a price target of EUR 18. Analysts from Commerzbank, Kempler or GBC also recommend buying.

time to read: 1 minutes by Mario Hose


 

Market leader in the growing German market for beauty treatments

With more than 200,000 treatments per year, M1 is the market leader for beauty treatments in Germany and has an estimated market share of 20 to 25% in non-surgical injectable treatments. Thanks to a combination of high quality treatments and cost leadership based on economies of scale in treatments and purchasing, M1 clinics have started to build a strong brand across Germany and launch their own M1 Select skincare range.

Prospects for economies of scale with limited risk

For further market penetration, M1 is currently expanding in German top 2 cities with 300,000 inhabitants. Thanks to its capital-saving business model and variable salary structures for doctors, the economic conditions are very favourable. This is offset by the economies of scale described above. For example, Berenberg assumes that M1 Kliniken will generate an attractive ROCE of more than 20% by 2021.

Growth through international expansion

M1 Kliniken plans to double the number of treatment units from 24 at the end of 2018 to 50 by the end of 2020, 20 of which will be outside Germany. The target markets are nearby Austria, Switzerland, the Netherlands as well as Great Britain and Australia. The goal of M1: An international market leader. For 2018-22, Berenberg forecasts average revenue growth of 17% p.a. and average EBIT growth of 30% p.a., driven mainly by the core segment Beauty.

Analysts with price targets up to EUR 21

With its buy recommendation, Berenberg joins the ranks of the positive analysts' comments. All the accompanying institutions - including Commerzbank and Bankhaus Metzler - are convinced that M1 Kliniken will also grow at double-digit rates in the coming years and recommend the share as a buy. The price targets range up to EUR 21 per share.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

30. January 2020 | 07:34 CET

After M1 now CR Capital with price jump: When does MPH share react?

  • Clinic

The holding company MPH Health Care AG can be pleased about the positive development of its investments. After the share price of M1 Klinken AG had increased significantly in recent weeks, driven among other things by positive analyst comments and the successful international expansion, the share of CR Capital Real Estate AG yesterday rose by 12.4% to EUR 36.20. The MPH share should also benefit from this development. The value of the M1 participation alone meanwhile exceeds the total market capitalisation of MPH of EUR 178 million. Thus, investors will receive the 50-percent shareholdings in CR Capital and Haemato AG with a combined market value of EUR 100 million free of charge. When does the MPH share react?

Read